Table 1: Baseline Demographics and Disease Characteristics in the Efficacy and Safety Populations of Study LIBRETTO-001.

	Efficacy Population N = 41	Safety Population N = 796
Sex, n (%)
Female	22 (54)	390 (49)
Male	19 (46)	406 (51)
Age at diagnosis (years), median [range]	50 [21, 85]	59 [15, 92]
Race, n (%)
Asian	10 (24)	185 (23)
Black or African American	2 (5)	25 (3)
White	28 (68)	545 (69)
Ethnicity, n (%)
Hispanic or Latino	3 (7)	40 (5)
Not Hispanic or Latino	37 (90)	737 (93)
Region, n (%)
Asia	12 (29)	185 (23)
Europe	3 (7)	123 (15)
North America	26 (63)	473 (59)
ECOG performance status at study entry, n (%)
0	14 (34)	294 (37)
1	25 (61)	464 (58)
History of Metastatic Disease
Yes	95%	98%
Number of Prior Lines of Therapy, median [range]	2 [0, 9]	1 [0, 15]

ECOG = Eastern Cooperative Oncology Group

Source: U.S. Food and Drug Administration. sNDA Multi-disciplinary Review and Evaluation and Approval Package: RETEVMO (selpercatinib).¹⁹